Toxicogenomics: "the call of the wild chip". by Iannaccone, P M
Toxicogenomics is a new undertaking in the pursuit of human genes
relevant to health risk from environmental toxicants and related stress.
Such stress spans a range of dire threats in the human condition from
ultraviolet to blue light, from particulate diesel exhaust to complex
chemical mixtures in the air, from threats in reused airplane air to
threats in herbal remedies, from threats in the food supply from pesti-
cides to threats from genetically modified organisms. This incredible
range of interest is embodied in the Environmental Genome Project,
sponsored and maintained in the interest of health by the National
Institute of Environmental Health Sciences (NIEHS), and about
which much has already been written (1–4). The aims of the
Environmental Genome Project include a characterization of impor-
tant genetic polymorphisms that alter protein function to the benefit
or to the determent of individuals upon exposure to environmental
stress. The completion of the human genome sequencing and hope-
fully its successful annotation is a major spur to accelerated progress in
the realm of environmental response genes. The program coordinates
a robust suite of extramurally funded research grants, Environmental
Health Centers and intramural research projects.
An important part of toxicogenomics is the widespread use of
high throughput expressed gene analysis or microarray technology
(5–7). In an absolutely amazing reversal of our traditional abhor-
rence of “descriptive” surveys, the scientific community has
embraced this latest technology as a relatively cheap, reliable, fast,
and effective way to protect populations and specific individuals
from environmental risk. Why should we be interested in this
approach to gene expression studies that uses high-level image pro-
cessing, high-fidelity polymerase chain reaction (PCR), and clever
hybridization protocols for the purpose of determining gene expres-
sion levels by comparison of different RNA populations? In a
word—scale. The simultaneous examination of a hundred genes is
descriptive; the simultaneous examination by comparison and clus-
tering of tens of thousands of genes is a new way to do science. 
Basically oligonucleotides or small pieces of cDNA are spotted
onto glass slides (or engineered into computer chips), and then RNAs
to be compared are hybridized after labeling with two different fluo-
rochromes: Cy3, which fluoresces red, and Cy5, which fluoresces
green. The genes studied may be selected for specific purposes, such
as those that are specific to environmental stress, or they may be
broad based for gene discovery purposes. Fluorescence appears in the
spots (or on the chip) and is detected with image analysis micro-
scopes, usually laser scanning microscopes (or a specialized chip read-
er). When there is a difference between expression levels in the RNAs
being compared, the fluorescent signal with one fluorochrome is
greater or less than that of the other. This is detected and quantified.
When the intensity with the two fluorochromes is the same (i.e.,
there is no difference in the two RNAs), then a merged (third) color
(yellow) appears. The method detects
relative changes in differential expres-
sion of populations of RNAs, but it
may be combined with other techniques such as real-time PCR (8) to
obtain quantitative data for selected genes. Depending on the avail-
ability of sequence information for the genome of interest and avail-
ability of probes from the sequences and the density of individual
spots, tens of thousands of expressed genes can be simultaneously
examined in a single or a few experiments.
A short parable, though. Suppose one had a large blank wall, and
onto this wall one painted tens of thousands of squares, either green,
red, or yellow. The squares might be painted in some randomly deter-
mined order or by a grand design. Now, suppose your funding
agency gave you 100–200 darts labeled “important new research
directions” and instructed you to throw them at the wall.
Importantly, you have a map of the squares on the wall, which, like
the map on the inside cover of a box of assorted chocolates, identifies
all of the squares as genes in a particular genome. You throw the darts
and then rush to the wall and look for the struck squares that are
green or red and declare them “changed gene expression levels.” From
those 100 or 200 you may have struck 50 or 60 squares that are
“changed gene expression levels.” From the 50 or 60 struck by chance
you might become genuinely excited by around 10 or 12 of the
“genes” that, because of the course of your own research, you believe
to be related to whatever question set you on your path to new
knowledge. The rest you would declare interesting, important, and
necessary to be cherished for a later time to figure out. 
While it is possible that gene expression profiling is described by
the foregoing parable, early results indicating specificity of array data
suggest that there is true inductive value from this process (9–11). It
is interesting to note that similar uncertainties existed early in the
days of gene sequencing. Importantly, the power of that paradigm
was realized when hundreds of researchers working independently of
each other on seemingly unrelated genes looked at each other’s
sequences and realized that we had much in common with each
other and with the species that we study. That was brought about, of
course, by widely accessible, accurate searchable databases of
sequence information that we all agreed to use (Table 1) and by dra-
matic increases in the efficiency of DNA sequencing. Can the same
approach work for microarray studies? It seems very probable.
Comparison of protocols, tissues, array production methodology,
and myriad other variables will lead to an understanding of which
technical details alter the results and which are not important. The
NIEHS has committed to creating the tools to do this, and it will
take the shape of the National Center for Toxicogenomics (NCT)
(24), which will incorporate the NIEHS Microarray Center. The
NCT will be at the NIEHS and will coordinate both extramural and
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An important part of the NCT will be the establishment and mainte-
nance of a toxicology database for microarray results. The NCT will
also support the ToxChip, already developed at the NIEHS (25).
Such a microarray database, GEO (Gene Expression Omnibus), is
already up and running at the National Center for Bioinformatics
(13). There are some problems with the database approach. For
example, why would anyone want to enter their data into the pro-
gram? And how can the quality of the data be assessed before they are
released to the public? Here some guidance comes from the other
major molecular biology databases. Data can be deposited and held
until publication. Peer-reviewed publication could be taken as a sur-
rogate for the legitimacy of the data, and data could be clustered by
experimental approach or by the type of question studied. Techniques
in tissue-based arrays could be enhanced through international work-
shops. These might be part of the National Toxicology Program
(NTP), which after all has the most complete set of toxicologic
response data in the world, with tissue repositories and sophisticated
methods for selection of compounds to study. 
Results from expressed gene array analyses are very sensitive to
the methodology used to establish the initial comparison of RNAs.
In some situations it is desirable to determine what genes are
expressed in tissues from one physiologic state versus another (26,27)
In these experiments, the way in which the tissue is obtained will
determine the value of the data, insofar as other differences will be
extant in the tissues besides those of primary interest. In some
instances it may be desirable to determine what genes are expressed
in the presence or absence of the expression of another gene of inter-
est (28,29). Such an approach is particularly appealing in cascades or
networks of interacting genes such as a signal transduction pathway
or a developmental hierarchy (30). Here we can choose a cell line,
transfect in a plasmid that forces high levels of expression of the gene
of interest, and then determine what genes change expression levels.
The cell line chosen for such an experiment is important. The gene
of interest, if transiently expressed, could lead to some subset of
genes that respond. In contrast, if we use stable transfection, we
might find gene responses that are secondary to the drug selection
system. It could be important that there be a recognizable phenotype
which varies between the two states examined, although the genes
that determine the phenotype might not be related to the gene of
interest. It is important to realize that the fluorochromes vary in their
stability, so it is important to label the RNAs both ways; that is, a
reciprocal hybridization should be performed in which the Cy3-
labeled RNA is labeled with Cy5 and the results compared. Low-
abundance RNA may be lost, and subtle differences in RNA in states
that are compared may be lost due to poor signal-to-noise ratios.
However, low-abundance RNA and small changes in RNA level
might be very important. The RNA should not be converted to
cDNA probes because this may skew results due to preferential ampli-
fication of some RNAs relative to others. Even though highly efficient
laser scanners and chip readers have been developed and fairly high-
density spotted arrays can be managed, the manner in which the array
is produced is very important. Poor spot production or misarranged
spot reading can cause artifacts in the results. 
Particularly appealing is the opportunity to profile conditions
(9,31). For example, if in a difficult diagnostic differential we could
establish that a given set of genes was expressed in one disease state
but a different set of genes was expressed in another disease state, then
determining which genes are expressed in an unknown case could
lead to more informed diagnosis (9,11). In stratifying patients for
treatment, prognosis, and research, such an approach is particularly
useful (32). Here one needs some way of knowing a priori what a
given sample is in order to determine the gene expression profile; but
if that can be done with confidence, what is the value in the end of
knowing the profile? In this circumstance we might hope to use a
prospective approach that allows elucidation of the correct diagnosis
after the fact by the behavior of the disease and with appropriately
selected individuals whose RNA can be examined. Moreover, once
the analytical method is established, we might expect that it would be
rapid and highly reproducible.
A logical extension of the approach of expressed gene profiling is
to study physiologic response to environmental stress, in particular
toxic exposure, and to determine for any given class of toxicants
what genes alter expression in stereotypical ways in a standardized
exposure protocol, either of intact test animals or particular cell
lines. In this way it seems entirely possible to create a toxicant class-
specific profile or fingerprint of expressed genes (25,34–36). The
appeal is that then we need only to repeat the exposure protocol for
an unknown chemical and declare it dangerous or safe depending
on the genes whose expression is altered in the exposure protocol.
Obviously the quality of the resulting profiles and their usefulness
will depend on the exposure protocol and its appropriateness to the
supposed class of the toxicant. Moreover, it will depend on the clus-
ter of toxicants included in a class. If the class of toxicants is too
broad, too many genes would be expressed and the genes would not
be specific; if the class of toxicants is too narrow, there could be
almost as many classes as chemicals to be studied and the applica-
tion of the profile to the chemical would become hopelessly ad hoc.
Indeed microarrays that allow the examination of toxic responses
are already available and under close scrutiny (25). 
There are issues that current approaches cannot fully address. In
complex signal transduction pathways, the activation of transcrip-
tion factors is frequently the result of protein–protein interactions
and not solely the result of genetic regulation. For example, in the
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Table 1. Web-based resources for toxicogenomics.
Tool Related operations National and international databases Reference 
Overview (12)
Gene expression profiling  cDNA microarrays Gene Expression Omnibus (13)
Transcriptome Expressed sequence tags  UniGene  (14)
Genomics Genebank LocusLink (15)
Gene mapping Anonymous markers GeneMap (human) (16)
Radiation hybrid maps
Polymorphisms
Species-specific RatMap (rat) (17)
Rat Genome Database (rat) (18)
FlyBase (Drosophila) (19)
Mouse Genome Informatics (mouse) (20)
Proteomics  Molecular modeling Protein Data Bank (21)
Crystallographic coordinates SwissProt (22)
Molecular Modeling Database (23)
Phenotyping  Tissue arrays Not organizedSonic hedgehog–Patched–GLI pathway (36,37) the transcription
factors GLI1 and GLI3 are tethered to cytoskeletal elements. In the
presence of signaling they are released to be transported to the
nucleus as a result of an activation mechanism that is not well
worked out, but certainly involves the cleavage of GLI3 and proba-
bly phosphorylaton of the binding proteins. Modification of one of
these binding proteins, Slimb, may be critical to the activation of
the transcription factors. Precisely how this occurs and which other
helper proteins are involved in the process will require the same type
of high throughput large-scale technology currently being applied to
expressed gene sets. Technologies are currently being developed that
will allow this (38), and they no doubt will be important in our
study of environmental stress response and attempts to develop
toxic signatures for unknown compounds. Even at the genetic level,
not all regulation will occur at the level of RNA transcription and
may not be easily detected by subtraction type strategies. For exam-
ple, the regulation of protein production through translation con-
trol is an important aspect of several genetic pathways. In the case of
Tra 2 in Caenorhabditis elegans and GLI1 in humans, the 3´UTR in
the transcribed RNA contains an element that binds a regulatory
protein(s) which leads to shortening of the poly A(+) tail and results
in lower levels of protein production (39–41). This mechanism and
the regulatory binding proteins are conserved from the worm to ver-
tebrates. Clearly, the binding proteins and the elements they bind to
are targets of environmental stress. Microarray data cannot help to
elucidate regulation that results from subcellular compartmentaliza-
tion of molecules, as in the case of p53 or cyclins. Where regulation
results from reversible phosphorylation or from ubiquination, the
gene expression data will not be helpful. 
Arguably the largest, most important environmental challenge
facing the American population in the next 25 years is air pollution.
Purely as a quantitative matter, the volume of environmental stressors
that we expose ourselves to, the sheer surface area of the exposure in
our bodies (i.e., the total airway surface area), and the complexity of
the chemistry behind it should be compelling enough. When we con-
sider the extraordinary growth of the sources of air pollution in this
country, it is hard to imagine a more important environmental health
issue. A wide variety of serious pulmonary diseases have not been well
characterized, and there is a major need to establish paradigms in
health studies that cross over the traditional emphasis on chemistry of
exposure versus the study of pathology of lung diseases. This is partic-
ularly true of childhood morbidity. In many children’s hospitals pul-
munary diseases such as asthma and cystic fibrosis represent leading
causes of admission. It is important to consider that events in child-
hood can be precursors of adult chronic disease, greatly increasing the
burden on society. Because these events have environmental compo-
nents, we should establish ways to study pulmonary disease in the
context of the complex chemistry of air pollution. This will require
sophisticated epidemiology, interventional epidemiology, and robust
studies in pulmonary biology. The new genomic information and
toolboxes may lead to further progress. 
It may be possible to screen biological samples obtained from
workers at Superfund sites for the adverse effects of exposure to com-
pounds present in the site. Although the Superfund project has made
important advances in public health in the United States, we have a
great deal to learn about the effects on workers at these sites.
Moreover, we are now beginning to realize the full magnitude of
these sites. As we begin to deal with seriously contaminated sites in
the Department of Defense and the Department of Energy, the mag-
nitude of true cleanup problems will strike home. We should be pre-
pared to understand the effects on workers performing these
cleanups. Once we know a suite of genes that are important in health
outcomes at such sites, it may be possible to use real time PCR (8)
on the spot as a signature of both exposure and risk.
We must continue to grapple with the question of how the mass
of data that will be generated in the next five years can be translated
into experiments which will help regulators. One need of toxicoge-
nomics involves the development of sound policy that must be
based in good science. The challenge is to first create the good sci-
ence, then to generate the discussion that informs policy. The stan-
dards of analysis, toxicogenomics databases, and public discussion
can provide a platform that supports the creation of good science.
The challenge will be to figure out how.
Many people who are worried about environmental stress won-
der if a given exposure in a given setting will pose a threat to an indi-
vidual’s health. What damage occurs if a cloud of diesel exhaust
blows in your face? What is the recovery phase from the exposure?
What is the health consequence? How frequently does the exposure
need to occur before these health effects are permanent? The answers
will depend, in part, on the effects of polymorphisms in the response
genes, and these are not yet fully known. It will be important to
coordinate the efforts of the Environmental Genome Program to
find the meaningful polymorphisms with gene expression profiling.
Exposure effects present a longitudinal problem: If the relevant tissue
could be obtained from the relevant population, the throughput
potential of the new toxicogenomics technologies could allow the
dimension of time in accumulated exposure risk to health to be
addressed. The challenge is to determine how.
There are large human cohort studies under way nationally in
several important areas. For example, the National Cancer Institute
and the NIEHS are accumulating long-term data from tens of thou-
sands of agricultural workers with respect to pesticide exposure. Can
the tissue and data from the pesticide study be linked to gene
expression studies in a meaningful way? The throughput potential
of the technologies discussed above should allow this, but we must
figure out how to do it.
There is a great deal of evidence that points to the effects of
environmental stress on infectious disease outcomes. It seems
axiomatic that there are important interactions of toxic exposure
with pathogens that will effect health outcomes. Can expressed gene
array data, gene polymorphism data, or human sequencing lead to
identification of overlapping gene pathways in pathogen response?
The completion of the Drosophila genome led to a number of
exciting intellectual developments. Among these was a change in
biomedical research paradigms toward consortia or engineering
models of cooperative effort. This approach has been used in the
past, but never, I believe, on such a scale. Another exciting develop-
ment was the manner in which the genome was annotated and the
information that flowed from the annotation (42). This approach to
a massive data set may inform the growing field of toxicogenomics.
Can there be an environmental response gene annotation emphasis
on the human genome project data?
As we look back over the past 12 or 15 years of genetics, we ask
ourselves what we have learned about large efforts and the payoff
they can have for important advances and for the growth of the gen-
eral body of knowledge. What tools have survived the test of time
(even though relatively short) and the test of utility? The pioneering
efforts of sequence databases, protein structure data, and the accessi-
ble tools that allow meaningful use of the data are at the forefront.
Rapid emergence of computing tools that do not require intimate
knowledge of computer architecture to operate them have allowed
important discovery, new knowledge, and, importantly, new experi-
mental designs to flourish. The expressed sequence tag (EST) pro-
grams have not only facilitated physical mapping of chromosomes
but have allowed innovative use of genome-wide information. The
involvement of the National Center for Bioinformatics in the cre-
ation of a database of unique genes in the EST pool [UniGene (14)]
has provided highly accessible information and clone sources to
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resources important to the range of molecular techniques in toxi-
cogenomics (sequencing, polymorphisms, phenotyping, expressed
gene microarrays, proteomics) will become available and widely used.
The development of tissue arrays should offer a new chance for the
NTP to provide a leap forward in our understanding of non-cancer
end points of environmental stress. The NTP has a huge collection
of tissue and data from animals exposed to nominated compounds
that could be used to determine the longitudinal response of envi-
ronmentally sensitive genes to exposure. The Environmental
Genome Project will also develop such a repository. The Agricultural
Health Study will likely develop a repository that could also be used
in this way. I hope that the information and tissues can be made
broadly available to the scientific community so that they can be
fully used to the benefit of public health.
As the United States continues to struggle with a toxic legacy and
with an ever-increasing burden of environmental stress, especially
from air pollution, new methodologies to assess risk to both popula-
tions and individuals must be put in place for our protection. How
will the scientific community respond to this challenge? In what ways
will the genetic revolution of the past several decades contribute to
this vital cause? We may hope that as toxicogenomics approaches
maturity, the concentration of a suite of tools and the management of
large data sets can lead to a point where meaningful science will guide
public health policy and minimize personal health risk.
Philip M. Iannaccone
Department of Pediatrics
Northwestern University Medical School 
The Children’s Memorial Institute for Education and Research
Chicago, Illinois
E-mail: pmi@nwu.edu
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